Clinical Trials Logo

Anemia clinical trials

View clinical trials related to Anemia.

Filter by:

NCT ID: NCT06198790 Not yet recruiting - Anemia Clinical Trials

Postoperative Anemia After Bariatric Surgery

Start date: February 1, 2024
Phase:
Study type: Observational [Patient Registry]

To investigate the real incidence of short and long-term anemia after bariatric surgery, and explore the risk factors.

NCT ID: NCT06176430 Not yet recruiting - Cerebral Palsy Clinical Trials

Comparison of Twice Weekly Versus Daily Iron Therapy in Treating Anemia in Children With Cerebral Palsy

Start date: February 1, 2024
Phase: Phase 4
Study type: Interventional

a randomized clinical trial to compare the effect of twice weekly versus daily iron therapy in treating anemia in children with cerebral palsy, to be conducted at Department of pediatric medicine children's hospital PIMS islamabad.

NCT ID: NCT06175117 Not yet recruiting - Postpartum Anemia Clinical Trials

Clinical Study on the Treatment of Postpartum Anemia With Compound E Jiao Jiang(cEJJ)

Start date: December 2023
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial] is to compare the effect of compound E Jiao Jiang(cEJJ)combined with iron decoction on postpartum anemia.The main questions it aims to answer are: To evaluate the effectiveness of compound E Jiao Jiang(cEJJ) in the treatment of postpartum anemia. To evaluate the safety of compound E Jiao Jiang(cEJJ) in the treatment of postpartum anemia. To explore the effect of compound ejiao decoction on improving anxiety, depression, sleep and fatigue in postpartum anemia patients. Participants will be randomly assigned (like flipping a coin) to either the trial group or the control group (with a 50% chance of being assigned to either group), where the trial group will receive the compound E Jiao Jiang(cEJJ) + ferrous succinate tablet, and the control group will receive the compound E Jiao Jiang(cEJJ)placebo + ferrous succinate tablet. The compound E Jiao Jiang(cEJJ)placebo is the same/similar to the compound E Jiao Jiang(cEJJ) in terms of appearance, smell and taste, but has no therapeutic effect.And participants need to return to the research center on time for relevant examinations according to the protocol requirements.

NCT ID: NCT06144749 Not yet recruiting - Anemia, Sickle Cell Clinical Trials

A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)

Start date: May 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multi-center, open label Phase 2a clinical trial in subjects with sickle cell disease to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of HBI-002, an orally administered liquid containing carbon monoxide (CO), with doses daily for 14 days.

NCT ID: NCT06096103 Not yet recruiting - Clinical trials for Anemia, Iron Deficiency

A Clinical Study to Check the Safety and Effectiveness of Botanical Extract Standardized for Iron + Vitamin c and Botanical Extract Standardized for Iron in Adult Human Subjects With Anemia or Iron-deficiency Anemia

Start date: November 15, 2023
Phase: N/A
Study type: Interventional

A randomized, double-blind, parallel, three-arms, placebo-controlled, safety and efficacy study of Botanical Extract Standardized for Iron + Vitamin C and Botanical Extract Standardized for Iron in adult human subjects with anemia or iron-deficiency anemia. A total of up to 96 adult male and female subjects of age 26 to 55 years (32 subjects/arm) will be enrolled to get 90 evaluable subjects (30 subjects/arm) in the study

NCT ID: NCT06079918 Not yet recruiting - Pregnancy Related Clinical Trials

Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania

MMS-MAP
Start date: September 2024
Phase: Phase 3
Study type: Interventional

This is an individually randomized controlled trial to assess the effect of multiple micronutrient supplements (MMS) containing 60 and 45 mg iron as compared to MMS containing 30 mg of iron (standard UNIMMAP formulation) on maternal moderate or severe anemia. This study will help inform countries like Tanzania that currently use IFA containing 60 mg of iron regarding the dose of iron to use in MMS.

NCT ID: NCT06075043 Not yet recruiting - Clinical trials for Cancer-Related Anemia

A Study of AND017 to Treat Cancer Related Anemia in Patients Not Receiving Chemotherapy

Start date: December 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of various doses of AND017 after 6 weeks of treatment in subjects with anemia of cancer who are not receiving chemotherapy.

NCT ID: NCT06075030 Not yet recruiting - Clinical trials for Chemotherapy Induced Anemia

A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy

Start date: December 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of AND017 after 6 weeks of treatment in patients with cancer-related anemia who are receiving chemotherapy.

NCT ID: NCT06061393 Not yet recruiting - Clinical trials for Anemia, Iron Deficiency

Comparison Between Outcomes of Pregnant Women Treated With Ferinject vs. Venofer for Iron Deficiency Anemia

Start date: October 30, 2023
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare maternal outcomes such as increased hemoglobin need for blood transfusion and hemoglobin level before and post partum in women with hemoglobin <9 gr/dl , treated with venofer and women treated with ferinject.

NCT ID: NCT06053866 Not yet recruiting - Clinical trials for Erythropoietin Resistant Anemia (EPO Resistant Anemia)

Prevalence of Erythropoiesis Stimulating Agents Hyporesponsiveness in Dialysis Patients in Assiut University Hospital

Start date: February 1, 2024
Phase:
Study type: Observational

- The prevalence of erthropoietin stimulating agents hyporesponsiveness in hemodialysis patients in Assiut university hospital - Assessment of cardiovascular diseases risk in patients with erythropoiesis stimulating agents hyporesponsiveness in hemodialysis patients in Assiut university hospital